ZyVersa Therapeutics (NASDAQ:ZVSA) (NASDAQ: ZVSA) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, dedicated to discovering and developing novel therapies for hematologic malignancies. The company’s research and development efforts focus on targeting unmet needs in acute and chronic blood cancers, including relapsed or refractory leukemias and lymphomas. Through a proprietary drug discovery platform, ZyVersa advances both biologic and small-molecule candidates designed to improve patient outcomes and overcome resistance to existing treatments.
Among ZyVersa’s lead programs is a next-generation bispecific antibody engineered to engage both CD19 and CD22 antigens on malignant B cells, offering a dual-target approach for patients with relapsed or refractory B-cell acute lymphoblastic leukemia. In parallel, the company is advancing a novel small-molecule BCL-2 inhibitor aimed at preventing tumor survival signals in mantle cell lymphoma and certain chronic lymphocytic leukemias. These assets have demonstrated encouraging preclinical activity and are currently being evaluated in Phase 1/2 clinical trials across multiple U.S. and European oncology centers.
To support global development, ZyVersa collaborates with leading contract manufacturing organizations in North America and Europe, ensuring scalable production of both antibody and small-molecule drug candidates. The company maintains active dialogues with regulatory authorities, including the U.S. Food and Drug Administration and the European Medicines Agency, to secure expedited pathways such as Breakthrough Therapy and PRIME designations. ZyVersa also works closely with academic institutes and patient advocacy groups to enrich trial design and broaden patient access.
Leadership at ZyVersa combines deep expertise in oncology drug development with seasoned operational management. Chief Executive Officer Dr. Amanda Parker, Ph.D., previously served as Vice President of Clinical Research at a major biotechnology firm, overseeing multiple oncology programs from early discovery through regulatory approval. Chief Financial Officer Michael Lee brings over a decade of experience in life-science finance and strategic transactions. Together with an advisory board of industry veterans, this team positions ZyVersa to advance its pipeline toward meaningful clinical milestones and potential regulatory approvals.
